Real-World Studies
Trabectedin plus PLD shows activity in post-PARPi ovarian cancer cohort
Amenabar et alGynecologic Oncology Reports
Optimal therapeutic sequencing remains an unresolved clinical dilemma in recurrent ovarian carcinoma following progression on poly-ADP-ribose polymerase inhibitors (PARPi), particularly within the partially platinum-sensitive window (platinum-free interval of 6 to 12 months). A single-center retrospective real-world study assessed the clinical outcomes, safety profile, and subsequent treatment pathways of trabectedin combined with pegylated liposomal doxorubicin (PLD) in this clinical setting.
The analysis included 25 heavily pretreated patients with a median age of 68.8 years, a median platinum-free interval of 7.0 months, and a median of three previous lines of therapy. Combination therapy with trabectedin and PLD exhibited clear clinical activity, achieving an objective response rate (ORR) of 24.0% and a disease control rate (DCR) of 64.0%. Patients achieved a median progression-free survival (PFS) of 7.9 months and a median overall survival (OS) of 19.9 months.
Notably, sequential treatment pathways were preserved; 76.0% of patients successfully transitioned to subsequent platinum-based chemotherapy after disease progression on the doublet. Among patients receiving immediate platinum rechallenge, the ORR reached 33.3%. Toxicities were primarily hematological and consistent with known class effects, with no unexpected safety signals observed. These findings demonstrate that trabectedin plus PLD represents an effective non-platinum bridging strategy to prolong the platinum-free interval and retain subsequent platinum sensitivity in selected post-PARPi ovarian cancer patients.
Key Takeaways
- Trabectedin plus pegylated liposomal doxorubicin achieved an objective response rate of 24.0%, a disease control rate of 64.0%, a median progression-free survival of 7.9 months, and a median overall survival of 19.9 months in recurrent ovarian cancer following PARP inhibitor progression.
- Following progression on trabectedin plus pegylated liposomal doxorubicin, 76.0% of patients successfully transitioned to subsequent platinum-based therapy, achieving an objective response rate of 33.3% upon immediate platinum rechallenge.
- Adverse events were predominantly hematological, with no unexpected safety signals reported.
Read the original sourceGynecologic Oncology Reports
